Alli available soon?
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline appears confident that issues raised in FDA's "approvable" letter for the weight-loss drug Alli (orlistat 60 mg) can be resolved swiftly. The firm "expects to respond to [FDA's April 6 approvable letter] shortly and to receive approval for the product" in the second half of 2006, the firm announces in a first-quarter earnings release April 27. The company previously has stated that it is aiming to make an OTC version of the weight-loss drug, sold by prescription as Xenical, available by mid 2006. The firm reported a strong first quarter during an earnings call, with Consumer Healthcare sales increasing 6% to $1.34 bil. ($1.75=£1) over the prior-year period. The increase was driven by sales growth in Europe and the international market, as sales in North America dropped 2%. Oral care sales grew 7% to $423.5 mil., driven primarily by Sensodyne's 21% sales growth; Aquafresh remained level at $127.75 mil. OTC drug sales increased 3% to $654.5 mil. for the quarter, while smoking cessation product revenues grew 5% to $162.7 mil...
You may also be interested in...
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.